Best Obesity Companies in United States
The 115 best Obesity companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Enveda.
Ranked by disclosed equity funding and recent momentum, the 115 Obesity companies tracked across the United States have pulled in $5.0 billion in total disclosed funding, and that number alone tells you how seriously capital is chasing this space. Enveda leads the directory at $505M raised, with Kailera close behind at $400M and Corxel at $287M. One unicorn has cleared the threshold. The investor roster, HHS, Domain Associates, Hercules Capital, RTW Investments, and SV Health Investors, reads like a who's who of biotech conviction. And with diagnosed prevalent cases rising and new drug therapies accelerating through clinical trials, community-based research infrastructure is becoming a real competitive variable, not just a regulatory checkbox.
The broader picture has some friction in it, though. Counterfeit GLP-1 drugs are proliferating globally, a supply-chain and reputational risk that legitimate filers here have to price into their go-to-market thinking. I'd also watch pricing pressure: Emcure's recent Poviztra price cut in India signals that semaglutide economics are shifting fast even outside U.S. borders. So what does that mean for domestic players still burning through pre-revenue runway? It means the funding advantage matters more, not less, and the directory below is where you start sorting who actually has it.
Ranked: Best Obesity companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Enveda 🦄 AI-based platform to decipher the chemistry of nature and develop new medicines 72Funding top 12%Moat top 32%Growth top 35%Market top 44% All 8 signals ▾Fundingtop 12% Moattop 32% Growthtop 35% Markettop 44% AItop 45% Talentbottom 49% Globalbottom 48% Techbottom 46% Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Moat: Unicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 72/100 | $505M | 9 mo ago | — | 2019 | Viswa Colluru Founder & CEO | — | — | — |
| 2 | Carmot Developer of disease-modifying therapies to treat metabolic diseases | $401M | 36 mo ago | 50 | 2008 | Heather Turner CEO | — | — | — |
| 3 | Kailera Developer of therapies for treating obesity and related conditions 60Funding top 12%Growth top 20%News top 22%Moat top 31% All 8 signals ▾Fundingtop 12% Growthtop 20% Newstop 22% Moattop 31% Techtop 40% Talentbottom 41% Globalbottom 38% Marketbottom 36% Funding: Raised $400M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $400M | 8 mo ago | — | 2024 | Ron Renaud Founder & CEO | 6 signals IPO · Leadership | — | 1 internship |
| 4 | BioAge Labs Provider of a bioinformatics platform for biomarkers and drug discovery | $294M | 28 mo ago | 43 43 → 100 (+133%) | — | — | — | 101 patents NLRP3 inflammasome inhibitors and apelin receptor modulators for BBB, muscle, weight therapies | 1 launch |
| 5 | CORXEL Developer of therapies for patients with cardiometabolic conditions | $287M | 4 mo ago | — | 2019 | Sandy Mou CEO | — | — | — |
| 6 | Vivus Developer of therapeutic solutions for obesity and sexual health | $253M | 157 mo ago | 59 | 1991 | Kent Blakely Founder | — | 254 patents Combination drug formulations and controlled-release delivery for obesity, pulmonary hypertension, and sleep apnea | — |
| 7 | Rani Therapeutics Developer of technology for the oral delivery of large drug molecules 72Growth top 22%Funding top 23%Patents top 24%Talent top 27% All 11 signals ▾Growthtop 22% Fundingtop 23% Patentstop 24% Talenttop 27% Innovationtop 28% Newstop 30% Moattop 35% Techtop 45% Marketbottom 49% Fin. healthbottom 44% Globalbottom 42% Growth: Revenue +59% YoY · Fresh capital in last 24 mo Funding: Raised $234M across 6 rounds · 6 rounds over 13 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $234M | 7 mo ago | 163 | 2012 | Mir Imran Founder | 16 signals ▲167% Leadership · Earnings · Funding | 456 patents Oral ingestible devices for delivering biologic therapeutics to the gastrointestinal tract | 1 launch |
| 8 | Structure Developer of oral small molecule drugs for chronic diseases | $191M | 46 mo ago | 93 93 → 232 (+149%) | 2017 | — | 3 signals ▼77% Earnings · Leadership | — | — |
| 9 | Gelesis Satiety induction through hydrogel capsules | $182M | 78 mo ago | 93 | 2006 | Yishai Zohar Founder & CEO | — | 173 patents Hydrogel-based oral therapeutics for obesity, constipation, and microbiome modulation | — |
| 10 | Allurion Developer of Gastric Balloon device for weight loss management 50Funding top 22%Customers top 23%Product top 24%Tech top 26% All 13 signals ▾Fundingtop 22% Customerstop 23% Producttop 24% Techtop 26% Moattop 38% Markettop 40% Innovationtop 50% Talentbottom 49% Patentsbottom 42% Globalbottom 42% Newsbottom 36% Fin. healthbottom 35% Growthbottom 29% Funding: Raised $151M across 15 rounds · 15 rounds over 14 yrs (1.1/yr) Customers: Play-Store rating 4.75★ across 1,421 ratings (1 apps) · Review volume +53% in 6 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $151M | 7 mo ago | 252 | 2009 | Samuel Levy Founder | — | 38 patents Temporary intragastric implant deployment systems for minimally invasive obesity treatment | 1 award |
| 11 | Intrapace Laparoscopically inserted pacemaker to stimulate Stomach | $143M | 153 mo ago | 1 | 2001 | Mir Imran Founder | — | 154 patents Implantable gastric devices and sensor feedback systems for obesity treatment | — |
| 12 | Aardark Therapeutics Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders | $138M | 25 mo ago | 10 | 2017 | Tien Lee CEO | 8 signals ▲33% Announcements · Leadership · IPO | — | — |
| 13 | MeiraGTx Developer of gene therapies for ocular and neurodegenerative diseases | $130M | 31 mo ago | 358 358 → 419 (+17%) | 2015 | — | 3 signals ▼73% Earnings | 14 patents Therapeutic modulation of the retromer complex for neurodegenerative disease treatment | — |
| 14 | HighTide Therapeutics Developer of small molecule based therapeutics for the treatment of liver, gastrointestinal, and metabolic… | $107M | 41 mo ago | 68 | 2011 | — | — | — | 1 launch |
| 15 | ModaThera Provider of medical devices for obesity treatment and metabolic disease management | $103M | 14 mo ago | 54 | 2002 | — | — | — | — |
| 16 | ReShape A dual intra-gastric balloon system for weight loss | $90M | 112 mo ago | 29 | 2005 | Michael Mangano CEO | — | — | — |
| 17 | GI Windows Revolutionizing surgical anastomosis with innovative magnetic technology for less invasive procedures | $89M | 20 mo ago | 15 | 2012 | — | — | 132 patents Magnetic-assisted surgical anastomosis and endoscopic navigation devices for minimally invasive procedures | 1 partnership |
| 18 | Apollo Endo Developer of therapeutic devices for obesity and other GI disorders | $80M | 71 mo ago | 132 | 2005 | — | — | — | — |
| 19 | BAROnova Satiety induction through endoscopically introduced Transpyloric shuttle | $78M | 126 mo ago | 1 | 2006 | Hugh Narciso President & CEO | — | 112 patents Obesity treatment via endoscopic gastric occlusion and gastrointestinal stimulation devices. | — |
| 20 | Orexigen Therapeutics Developing and marketing drugs for the treatment of obesity. | $76M | 111 mo ago | 132 | 2002 | — | — | 380 patents Combination naltrexone‑bupropion pharmaceutical formulations for obesity and cardiometabolic risk reduction | — |
| 21 | Versanis Bio Developer of therapeutics for the treatment of obesity | $70M | 57 mo ago | 21 | 2020 | — | — | — | — |
| 22 | Obalon Weight loss solutions: LAP-BAND, ReShape Vest, Obalon balloon system | $64M | 93 mo ago | 1 | 2008 | — | — | — | — |
| 23 | Satiety Device for transoral gastroplasty, an endoscopic approach to satiety induction | $64M | 200 mo ago | 10 | 2000 | — | — | 80 patents Minimally invasive gastric volume-reduction and partitioning devices for obesity therapy. | — |
| 24 | EnteroMedics Satiety induction through vagal nerve block | $62M | 104 mo ago | 63 | 2002 | — | — | 146 patents Implantable neuromodulation systems for metabolic and cardiovascular regulation | — |
| 25 | Altimmune Developer of vaccines for infectious disease including influenza, hepatitis B and solid tumors | $58M | 71 mo ago | 17 | 1997 | Vipin Garg CEO | 23 signals ▲92% Board · Acquisition · Earnings | 90 patents Vaccine and immunotherapy formulation technologies, including viral vectors, peptide vaccines, and adjuvant delivery. | — |
| 26 | i2o Therapeutics Provider of an oral drug delivery solution | $54M | 32 mo ago | 6 | 2019 | Samir Mitragotri Co-Founder | — | — | — |
| 27 | Juvena Therapeutics Company developing protein based therapies for sarcopenia and muscle regeneration 29Funding top 25%Moat top 31%Talent top 38%News bottom 42% All 7 signals ▾Fundingtop 25% Moattop 31% Talenttop 38% Newsbottom 42% Globalbottom 39% Marketbottom 34% Techbottom 28% Funding: Raised $50.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $50M | 11 mo ago | 30 | 2017 | Jeremy O'Connell Co-Founder & CSO | — | — | — |
| 28 | ValenTx Adjustable Endoluminal bypass sleeve for obesity treatment | $49M | 88 mo ago | 22 | 2002 | Jon Germain CEO | — | 97 patents Minimally invasive endoluminal gastrointestinal bypass and obesity treatment devices | — |
| 29 | USGI Medical Incisionless surgical solutions improving patient lives through innovative endoluminal technologies | $46M | 84 mo ago | 36 | 2001 | Scott Moonly CEO | — | 237 patents Surgical devices for anchoring and securing gastrointestinal implants and tissue | — |
| 30 | Reviva Pharmaceuticals Develops therapeutic drugs for treatment of central nervous system | $41M | 109 mo ago | 4 | 2006 | Laxminarayan Bhat President and CEO | 10 signals ▲25% Earnings · Funding · IPO | 161 patents Liposomal drug delivery of Brilaroxazine for psoriasis and arylpiperazine therapies for pulmonary fibrosis | — |
| 31 | Standard Bariatrics Provider of medical devices for the surgical treatment of obesity | $36M | 49 mo ago | 34 | 2014 | — | — | 238 patents Advanced surgical stapling and tissue‑migration control for minimally invasive procedures. | — |
| 32 | Halia Provider of chronic inflammation therapy | $30M | 11 mo ago | 18 | 2017 | Jared Bearss Co-Founder | — | — | — |
| 33 | Glyscend Developer of orally administered barrier pill for the treatment of diabetes and obesity | $25M | 72 mo ago | 9 | 2014 | — | — | 32 patents Boronic‑acid functionalized polymers for glucose sensing and drug delivery. | — |
| 34 | Graviton Bioscience Biotech company focused on developing therapies to cure diseases through restored homeostasis | $25M | 29 mo ago | — | 2023 | Samuel Waksal Chief Executive Officer | — | — | — |
| 35 | Syntis Provider of drug compounding services | $15M | 11 mo ago | 9 | 2021 | Robert Langer Co-Founder | — | — | — |
| 36 | Elira Developer of wearable device for controlling appetite | $11M | 41 mo ago | 12 | 2004 | Danika Harrison CEO & President | — | 41 patents Transcutaneous electrical stimulation devices for glucose‑guided weight loss and appetite control | — |
| 37 | Endevica Bio Developer of therapeutic drugs for the treatment of cancer cachexia | $10M | 41 mo ago | 5 | 2009 | Kenneth Gruber Founder & Chief Scientific Officer | — | — | 1 job opening |
| 38 | Abilita Therapeutics Developer of therapeutics to target membrane proteins | $9M | 17 mo ago | — | 2014 | Mauro Mileni Founder & CEO | — | — | — |
| 39 | GT Metabolic Solutions Developer of medical technology intended to revolutionize gastric bypass | $9M | 31 mo ago | 8 | 2020 | Thierry Thaure Co-Founder & CEO | — | 112 patents Magnetic compression devices for gastrointestinal anastomosis and organ sealing | — |
| 40 | Xeno Biosciences Developer of transformational therapies for metabolic diseases | $8M | 41 mo ago | 5 | 2015 | — | — | — | — |
| 41 | Response Pharmaceuticals Developer of therapeutics for side effects of neurology drugs | $8M | 24 mo ago | — | 2019 | Eric Keller CEO and Co-Founder | — | — | — |
| 42 | Hero Patch Developer of antibodies or small molecules for drug delivery | $8M | 36 mo ago | 14 | 2019 | Hojat Rezaei Co-Founder & CTO | — | — | — |
| 43 | Phenomix Sciences Provider of test for personalized management of obesity | $8M | 5 mo ago | 9 | 2017 | Michael Camilleri Co-Founder | — | — | — |
| 44 | Remedy Plan Developing first-in-class NAMPT inhibitors for oncology, autoimmune, and metabolic diseases | $7M | 13 mo ago | 10 | 2011 | — | — | 24 patents Small‑molecule oncology drugs targeting cancer stem cells and NAMPT enzymes | — |
| 45 | Gila Therapeutics Developer of therapeutics for the treatment of obesity and cardiometabolic disorders | $5M | 30 mo ago | 1 | 2014 | Andres Acosta Co-Founder | — | — | — |
| 46 | Adipo Therapeutics Developer of therapeutic solutions for the treatment of obesity & diabetes | $4M | 19 mo ago | 3 | 2016 | Meng Deng Founder | — | — | — |
| 47 | Bfkw Satiety induction through gastric implant | $4M | 19 mo ago | 4 | 2004 | — | — | 164 patents Intraluminal medical device fixation and deployment systems for minimally invasive procedures. | — |
| 48 | Skye Bioscience Developer of cannabinoid-based therapies for the treatment of glaucoma and other diseases | $2M | 27 mo ago | 11 11 → 18 (+64%) | 2011 | Punit Dhillon President | 3 signals ▼25% Lawsuit | — | — |
| 49 | Vogenx Developer of therapeutics for the treatment of serious metabolic and gastrointestinal diseases | $750K | 6 mo ago | — | 2020 | James Green Chief Executive Officer | — | 9 patents Patents concentrated in health & consumer products | — |
Top 12 Obesity companies in United States
#1
Series D · Berkeley Heights, New Jersey · founded 2019$287Mraised▾
Developer of therapies for patients with cardiometabolic conditions. It offers a pipeline of treatments including an oral small molecule GLP-1 receptor agonist for the treatment of obesity and diabetes mellitus, JX10 is an investigational drug for acute ischemic stroke, and JX09 a next-generation highly selective aldosterone synthase inhibitor for hypertension, heart failure and chronic kidney disease.
- Jan 2026Series D$287M
#2
Enveda 🦄Series D · Boulder, Colorado · founded 2019$504.8Mraised▾
AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.
- Sep 2025Series D$150M
- Feb 2025Series C—
- Nov 2024Series C$130M
- Jun 2024Series B$55M
#3
Public · San Jose, California · founded 2012 · 163 employees$234.1Mraised▾
Developer of technology for the oral delivery of large drug molecules. The company has a proprietary platform is capable of delivering a wide range of biologics for the treatment of various chronic diseases. The company develops RaniPill capsule has broad applications for the treatment of acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohn’s disease, hemophilia, diabetes, among other diseases.
- Oct 2025Post IPO$60.3M
- Dec 2020Series E$69M
- Nov 2020Series E$50M
- Feb 2018Series E$53M
#4
Public · Waltham, Massachusetts · founded 2024$400Mraised▾
Developer of therapies for treating obesity and related conditions. It offers a pipeline of drug candidates which include KAI-9531 a GLP-1/GIP receptor dual agonist formulated as an injectable peptide, KAI-7535 is an oral small molecule, KAI-9531 is a GLP-1/GIP receptor, and KAI-9531 is a GLP-1/GIP receptor for the treatment of obesity and type 2 diabetes.
- Oct 2025Series B$600M
- Oct 2024Series A$400M
#5
Public · Wellesley, Massachusetts · founded 2009 · 252 employees$150.5Mraised▾
Developer of Gastric Balloon device for weight loss management. The Program targets obesity by combining a gastric balloon that occupies stomach space to promote fullness with behavioral coaching and an app for tracking progress.
- Nov 2025Post IPO$5M
- Jan 2025Post IPO$2.5M
- Apr 2024Post IPO$48M
- Dec 2023Post IPO$122.5K
#6
Acquired · Laguna Niguel, California · founded 2002 · 54 employees$103.1Mraised▾
Provider of medical devices for obesity treatment and metabolic disease management. It offers a portfolio of products and services designed to manage weight and address metabolic health. The offerings include devices like LAP-BAND and ReShape Vest, alongside programs such as ReShapeCare and ReShape Optimize. They focus on minimally invasive solutions and long-term weight loss strategies. The company provides resources for both professionals and patients, including an online institute. It is used in the field of obesity treatment, offering solutions that are anatomy-friendly and aim to improve patient outcomes.
- Apr 2025Grant (prize money)$331.5K
- Jan 2025Grant (prize money)$300K
- Aug 2024Grant (prize money)$345.6K
- Sep 2023Grant (prize money)$331.5K
#7
Series A · Saint Paul, Minnesota · founded 2017 · 9 employees$7.6Mraised▾
Provider of test for personalized management of obesity. The company has developed a blood test that helps in weight loss management. It has used technology for using precision medicine for obesity treatment. The test assists with the diagnosis, medication, procedure selection, and more.
- Dec 2025Series A$2.5M
- Feb 2025Grant (prize money)$2M
- May 2024Grant (prize money)$2.3M
- Apr 2024Series A$5.5M
#8
Series B · San Mateo, California · founded 2017 · 30 employees$50Mraised▾
Juvena Therapeutics is engaged in the development of protein-based therapeutics that promote tissue generation in the elderly. The company has developed a discovery platform for screening restored muscle function which can be developed to other tissue types. The company has developed a protein cocktail which can improve the ability of aged muscle to heal and regenerate and also to look youthful and active.
- Jun 2025Series B$41M
- Nov 2022Series A$41M
- Sep 2021Grant (prize money)$254.3K
- Feb 2018Series A$4.3M
#9
Series C · Lehi, Utah · founded 2017 · 18 employees$30Mraised▾
Provider of chronic inflammation therapy. It offers APOE4 carriers that avoid Alzheimers due to protective mutations, HT-6184 enhances semaglutide efficacy while preserving lean mass for obesity, and resilience variants show immune system restoration via NEK7 inhibition for MDS.
- Jul 2025Series C$336.8K
- Jan 2024Series C$30M
#10
Series A · Boston, Massachusetts · founded 2021 · 9 employees$15.4Mraised▾
Operator of a late-stage preclinical platform intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling researchers to treat patients within a broader disease category.
- Jul 2025Grant (prize money)$5M
- Jul 2025Series A$33M
- May 2025Grant (prize money)$1.6M
- May 2025Grant (prize money)$1.6M
#11
Series B · West Bridgewater, Massachusetts · founded 2012 · 15 employees$89.1Mraised▾
Revolutionizing surgical anastomosis with innovative magnetic technology for less invasive procedures. This company is engineering a revolutionary anastomotic technology, marking a significant breakthrough in surgery. Their novel approach creates a magnetic anastomosis that forms an immediately patent lumen, showing superior healing compared to traditional methods. The technology aims to reshape surgical anastomotic procedures, bringing tangible benefits to patients and the healthcare system. They focus on less invasive surgery for both surgeons and patients. The team comprises accomplished leaders with expertise in bringing paradigm-changing medical technologies to market. They are committed to innovation in the medical device industry, specifically in surgical solutions.
- Oct 2024Series B$37M
- Jun 2022Series A$14.5M
- Aug 2020Series A$16.4M
- Dec 2019Series A$14.6M
#12
Series B · Washington, DC, District of Columbia · founded 2011 · 10 employees$6.7Mraised▾
Developing first-in-class NAMPT inhibitors for oncology, autoimmune, and metabolic diseases. This biotech company is pioneering a new approach to targeting NAMPT, a core regulator of human biology, to treat diseases. Their proprietary drug screening platform has led to novel drug chemistry and an unprecedented mechanism of action, avoiding the toxic effects of previous NAMPT-targeting drugs. They are focused on discovering and optimizing new drugs that target core vulnerabilities in cancer cells, autoimmune disorders, and metabolic diseases. The company's science pipeline includes programs in oncology, autoimmune diseases, and obesity. They aim to develop therapeutics that effectively block cancer recurrence and metastasis, as well as treat other diseases linked to NAMPT dysregulation.
- May 2025Series B$18M
- Dec 2019Series A$5.2M
- Nov 2018Series A$1.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Obesity coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding flat · growth flat
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.